MarketPulse
S

$SVRA

2 articles found
1 positive
0 negative
1 neutral
BenzingaBenzinga··Business Wire

Savara Clears FDA Hurdle for MOLBREEVI as Drug Advances Toward Autoimmune PAP Approval

Savara receives FDA Day 74 Letter for MOLBREEVI with no advisory committee meeting planned. PDUFA target date set for August 2026.
SVRAFDA approvalMOLBREEVI
BenzingaBenzinga··Business Wire

Savara to Present MOLBREEVI Progress at Miami Life Sciences Conference

Clinical-stage biotech $SVRA will present at 2026 Citizens Life Sciences Conference, showcasing progress on its Phase 3 rare respiratory disease program.
SVRAclinical-stagebiopharmaceutical